You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 27, 2024

~ Buy the ZEJULA (niraparib tosylate) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR ZEJULA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for zejula

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03207347 ↗	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Suspended	GlaxoSmithKline	Phase 2	2018-08-13	This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
NCT03207347 ↗	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Suspended	Tesaro, Inc.	Phase 2	2018-08-13	This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
NCT03207347 ↗	A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)	Suspended	University of Florida	Phase 2	2018-08-13	This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for zejula

Condition Name

Chart
Table

Condition Name for zejula
Intervention	Trials
Ovarian Cancer	12
Neoplasms	6
Ovarian Neoplasms	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for zejula
Intervention	Trials
Ovarian Neoplasms	18
Carcinoma, Ovarian Epithelial	16
Carcinoma	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for zejula

Trials by Country

Map
Table

Trials by Country for zejula
Location	Trials
United States	153
China	8
United Kingdom	8
Germany	8
Italy	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for zejula
Location	Trials
Massachusetts	13
California	12
Florida	10
North Carolina	8
New York	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for zejula

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for zejula
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	39
Phase 1/Phase 2	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for zejula
Clinical Trial Phase	Trials
Recruiting	26
Not yet recruiting	19
Active, not recruiting	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for zejula

Sponsor Name

Chart
Table

Sponsor Name for zejula
Sponsor	Trials
GlaxoSmithKline	22
Tesaro, Inc.	21
Massachusetts General Hospital	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for zejula
Sponsor	Trials
Other	85
Industry	66
NIH	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.